Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Experience from the PRESENT study

Diabetes, Obesity and Metabolism

Volumn 10, Issue 3, 2008, Pages 212-222

  Khutsoane, D ^a   Sharma, S K ^b   Almustafa, M ^c   Jang, H C ^d   Azar, S T ^e   Danciulescu, R ^f   Shestakova, M ^g   Ayad, N M A ^h   Guler, S ⁱ   Bech, O M ^j  

^a Bloemfontein Medi Clinic   (South Africa)

^b MG Medical College Jaipur   (India)

^c MUSTANSIRIYAH UNIVERSITY   (Iraq)

^d Seoul National University College of Medicine   (South Korea)

^e AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^f Nutrition and Metabolic Diseases 'N Paulescu'   (Romania)

^g N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^h Taiba Hospitals   (Kuwait)

ⁱ ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^j SIBS Novo Nordisk Translational Research Centre for PreDiabetes   (China)

more..

Author keywords

Biphasic insulin aspart 30; Clinical practice; Insulin analogue; Observational study; PRESENT study; Type 2 diabetes mellitus

Indexed keywords

BIGUANIDE; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIET RESTRICTION; DISEASE CONTROL; DISEASE DURATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EDEMA; ETHNIC DIFFERENCE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INDIA; IRAQ; JORDAN; KUWAIT; LEBANON; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; POSTPRANDIAL STATE; QATAR; REFRACTION ERROR; ROMANIA; RUSSIAN FEDERATION; SAUDI ARABIA; SIDE EFFECT; SOUTH AFRICA; SOUTH KOREA; TREATMENT DURATION; TURKEY (REPUBLIC); UNITED ARAB EMIRATES; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 39049090368     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00826.x     Document Type: Article

References (38)

1. American Diabetes Association. Standards of care for patients with diabetes mellitus (position statement). Diabetes Care 2001; 24 (Suppl. 1): S33-S43.
2. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetes patients. Diabetes Care 2003; 26: 881-885.
3. El-Kebbi IM, Ziemer DC, Cook CB, Gallina DL, Barnes CS, Phillips LS. Utility of casual postprandial glucose levels in type 2 diabetes management. Diabetes Care 2004; 27: 335-339.
4. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: The epidemiological evidence. Diabetologia 2001; 44: 2107-2114.
5. Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow up. Diabetologia 1996; 39: 1577-1583.
6. Sievers ML, Bennett P, Nelson RG. Effect of glycaemia on mortality in Pima Indians with type 2 diabetes. Diabetes 1999; 48: 896-902.
7. Esposito K, Giugliano D, Nappo F, Marfella R, for the Companion Postprandial Hyperglycaemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycaemia in type 2 diabetes mellitus. Circulation 2004; 110: 214-219.
8. Chiasson JL, Josee RG, Gomis R, Hanefeld M, Karasik A, Laakso M, for the STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension patients with impaired glucose tolerance. JAMA 2003; 290: 486-494.
9. de Backer G, Ambrosioni E, Borch-Johnson K et al. European guidelines on cardiovascular disease prevention in the clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-1610.
10. Leiter LA, Ceriello A, Davidson JA et al. Postprandial glucose regulation: New data and new implications. Clin Ther 2005; 27 (Suppl. B): S42-S56.
11. Christiansen JA, Vaz JA, Metalko Z, Bogoev M, Dedov I. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 446-454.
12. Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-265.
13. Jacobsen LV, Søgaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000; 56: 399-403.
14. Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: Analogue or human? Diabetes Obes Metab 2007; 9: 630-639.
15. Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006; 66: 31-49.
16. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: A randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002; 19: 393-399.
17. Boehm BO, Vaz JA, Brønsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med 2004; 15: 496-502.
18. Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/ 30 or NPH insulin in combination with metformin. J Diabetes Complications 2003; 17: 307-313.
19. Kapitza C, Rave K, Ostrowski K, Heise T, Heinemann L. Reduced postprandial glycaemic excursion with biphasic insulin aspart 30 injection immediately before a meal. Diabet Med 2004; 21: 497-501.
20. Warren ML, Conway MJ, Klaff LJ, Rosenstock J, Allen E. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients. Diabetes Res Clin Pract 2004; 66: 23-29.
21. Ligthelm RJ, Borzi V, Gumprecht J, Kawamori R, Yang WY, Valensi P. Importance of observational studies in clinical practice. Clin Ther 2007; 29: 1284-1292.
22. Joshi SR, Kalra S, Badgandi M, Rao YS, Chawla M. Designer insulins regimens in clinical practice -pilot multicenter Indian study. J Assoc Physicians India 2005; 53: 775-779.
23. Sridhar GR. Two regimens of twice-daily premix insulin analogue: An observational study. Diabetes Res Clin Pract 2006; 71: 105-107.
24. Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 2005; 281: 2005-2012.
25. Holman RR, Turner RC. Optimizing blood glucose control in type 2 diabetes: An approach based on fasting blood glucose measurements. Diabet Med 1988; 5: 582-588.
26. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
27. Garber AJ, Wahlen J, Wahl T et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006; 8: 58-66.
28. Kvapil M, Swatko A, Hilberg C, Shestakova M. Biphasic insulin aspart 30 plus metformin: An effective combination in type 2 diabetes. Diabetes Obes Metab 2006; 8: 39-48.
29. Davies M, Storms F, Shutler S et al. Improvement of glycaemic control in subjects with poorly controlled type 2 diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005; 28: 1282-1288.
30. Ligthelm RJ. Biphasic insulin aspart 30 (BIAsp 30) in clinical reality: experience from a Dutch practice. Diabetes 2007; 56 (Suppl. 1): A540.
31. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: Pathophysiology, frequency and effects of different treatment modalities. Diabetes Care 2005; 28: 2948-2961.
32. Mendoza A, Kim YN, Chernoff A. Hypoglycemia in hospitalized adult patients without diabetes. Endocr Pract 2005; 11: 91-96.
33. Guven M, Bayram F, Guven K, Kelestimur F. Evaluation of patients admitted with hypoglycaemia to a teaching hospital in Central Anatolia. Postgrad Med J 2000; 76: 150-152.
34. Davidson J, Vexiau P, Cucinotta D, Vaz J, Kawamori R. Biphasic insulin aspart 30: Literature review of adverse events associated with treatment. Clin Ther 2005; 27 (Suppl. B): S75-S88.
35. Kitzmiller JL, Main E, Ward B, Theiss T, Peterson DL. Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy. Diabetes Care 1999; 22: 874-876.
36. Roysarkar TK, Gupta A, Dash RJ, Dogra MR. Effect of insulin therapy on progression of retinopathy in non-insulin-dependent diabetes mellitus. Am J Ophthalmol 1993; 115: 560-574.
37. Henricsson M, Janzon L, Groop L. Progression of retinopathy after change of treatment from oral antihyperglycemic agents to insulin in patients with NIDDM. Diabetes Care 1995; 18: 1571-1576.
38. Llewelyn JG, Thomas PK, Fonseca V, King RHM, Dandona P. Acute painful diabetic neuropathy precipitated by strict glycemic control. Acta Neuropathol 1986; 72: 157-163.